Drug intelligence / Profile preview

KP-2303

Development stage: Preclinical
Lead developer: Kolon Pharma

Overview

KP-2303 is an early-stage drug candidate being developed by the Kolon Group (Kolon Pharma) for the treatment of atopic dermatitis. It is currently in the preclinical phase, specifically undergoing exploratory studies. As a proprietary pipeline asset, specific details regarding its molecular target, mechanism of action, and modality have not been publicly disclosed by the company.

Beyond the preview

Go deeper on KP-2303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KP-2303.

Explore the full profile